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Abstract To study the inXuence of microwave induced
thermo-chemotherapy on high-grade urothelial cell
carcinomas. Five groups of each three patients were
formed of whom initial biopsies and cystectomy sam-
ples were collected. Patients were treated 2 days prior
to cystectomy with mitomycin-C (group 1), hyperther-
mia (group 2) or thermo-chemotherapy (group 3).
Group 4 patients had been treated with a cycle of six
thermo-chemotherapy treatments prior to cystectomy
and group 5 patients served as control (no treatment).
Tumour samples were stained with Haematoxylin and
Eosin, monoclonal antibody Ki-67 and the monoclo-
nal antibody p53. In six out of the nine patients
treated with hyperthermia a decrease in proliferation
activity in the tumour was found. Seven out of nine
patients treated with hyperthermia showed a
decrease in p53 activity. A decrease in proliferation
activity and p53 activity illustrate the potential role of
thermo-chemotherapy as a promising intravesical
treatment.
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Introduction
Bladder cancer is the seventh most common cancer
worldwide, accounting for 3.2% of all cancers. In 2000
an estimated 260,000 new cases in men and 76,000 in
women were found worldwide [5]. The highest inci-
dence rates of bladder cancer in both sexes are
observed in Europe, North America and Australia
[12]. Bladder cancer incidence is still rising moderately
in most developed countries. Of all these malignant
bladder tumours, more than 90% are transitional cell
carcinomas of which two third is superWcial and one
third is muscle invasive. The management of these two
types of transitional cell carcinoma diVers enormously.
The management of superWcial bladder cancer consists
of transurethral resection in the Wrst place, whereas the
primary treatment for muscle invasive bladder cancer
consists of cystectomy, a complete diVerent approach.
After transurethral resection of a superWcial blad-
der tumour 30–85% of patients develop recurrences,
despite the most accurate resection technique. This
high risk of recurrences makes bladder cancer one of
the most prevalent human tumours. To decrease the
number of recurrences after transurethral resection,
patients are treated subsequently with chemothera-
peutic or immunotherapeutic agents. Immunotherapy,
usually BCG treatment, is more eVective than any
intravesical chemotherapeutic agent, but has more
serious and more frequent side eVects. So, there is a
need for more eVective treatment options or treat-
ment options with less frequent and less severe side
eVects. A new treatment option in patients with inter-
mediate to high risk tumours is the combination of
intravesical hyperthermia and intravesical chemother-
apy [2, 6, 15].
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The endocavitary location and ease of accessibility
by the urethra makes thermo-chemotherapy a good
therapeutic option for superWcial bladder cancer. Local
hyperthermia at temperatures of 40–44°C in combina-
tion with selected cytostatic agents in several tumours,
including transitional cell carcinoma, results in a syner-
gistic anti-tumour eVect [10].
In this descriptive study the inXuence of diVerent
treatment modalities on bladder tumours (thermo-che-
motherapy, chemotherapy and thermotherapy) was
investigated by several immunohistochemical stainings.
Methods
Subjects
The study included 15 patients with high-grade transi-
tional cell carcinoma of the bladder. All patients signed
a patient informed consent and all these patients were
facing cystectomy. The 15 patients were divided in Wve
groups with each three patients. Group 1 patients were
treated 2 days before cystectomy with an intravesical
mitomycin-C (MMC) instillation. After the bladder
was emptied, 20 mg MMC (Kyowa Hakko Kogyo Co.,
Tokyo, Japan) in 50 ml saline was instilled. In order to
stabilize the MMC concentration in the bladder
throughout the entire session, the bladder was emptied
after 30 min and with urine diluted solution was
replaced by a new solution containing 20 mg MMC.
Group 2 patients were treated 2 days before cystec-
tomy with sterile water and local hyperthermia. To
standardize treatments the instillation was replaced
after 30 min. The local microwave induced hyperther-
mia was delivered by the SB-TS 101 system as
described by Colombo et al. [3]. This system consists of
a 915 MHz intravesical microwave applicator that
delivers hyperthermia of the bladder walls via direct
irradiation. The applicator is part of the specially
designed 20F transurethral catheter. The catheter also
contains Wve thermocouples. Two thermocouples mea-
sure the temperature in the prostatic urethral tract; the
other three are spread out and pushed tangentially
against the posterior and lateral walls of the bladder.
To avoid urethral overheating, the solution is continu-
ously pumped out of the bladder and re-instilled after
being cooled. Hyperthermia was delivered within a
temperature range of 41–42°C.
Group 3 patients were treated 2 days before cystec-
tomy with two times 30 min intravesical MMC (20 mg
in 50 ml sterile water) combined with local microwave
induced hyperthermia delivered by the SB-TS 101 sys-
tem. Group 4 patients were treated with a cycle of six
thermo-chemotherapy treatments during the last
3 months. Finally, group 5 patients served as control
group. These patients did not receive any intravesical
instillations within 3 months prior to cystectomy.
Immunohistochemistry
All tumour tissue samples were Wxed in a 10% buVered
formaldehyde solution. The specimens were embedded
in paraYn blocks and sections of 4 m were cut. All
specimens were deparaVinized and stained with Hae-
matoxylin and Eosin. A microscopic examination of
the samples was performed and the extend of inXam-
mation (1+ to 3+) haemorrhage (1+ to 3+) were semi
quantitatively scored.
Ki-67, a nuclear protein present during phases G1,
S, G2 and M of cycling cells, is accepted as a good indi-
cator of cell proliferation [11]. Sections were deparaV-
inized and immersed in a 10 mM sodium citrate buVer
(pH 6.0) in a microwave oven for two times 5 min to
enhance antigen retrieval. After washing, the slides
were incubated with 0.3% H2O2 in methanol to
quench endogenous peroxidase activity. After incuba-
tion at room temperature for 2 h with the anti-Ki67
monoclonal antibody clone MIB-1 (BioGenex)
diluted 1:30, a biotinylated antibody that recognises
murine IgG (BioGenex) was applied for 20 min, fol-
lowed by incubation in streptavidin-peroxidase com-
plex (BioGenex) for 20 min. The peroxidase reaction
was developed using 0.5 mg/ml diaminobenzidine tetr-
ahydrochloride (Sigma) in 0.01% H2O2. Haematoxy-
lin was used as a light counter stain. The slides were
dehydrated and mounted with a xylene-soluble
mounting medium.
The mutated p53 tumour suppressor gene product
can be detected immunohistochemically and is associ-
ated with a lower survival in patients with bladder can-
cer [7]. Sections were deparaVinized and immersed in a
10 mM sodium citrate buVer (pH 6.0) in a microwave
oven for two times 5 min to enhance antigen retrieval.
After cooling down, 0.6% H2O2 in a 40% methanol
solution was used for 30 min to block endogenous per-
oxidase activity. Slides were pre-treated with 10% nor-
mal swine serum for 10 min to block non-speciWc
staining followed by adding primary antibody DO-7 for
1 h at 20°C. After extensive rinsing, sections were incu-
bated for 30 min with biotinylated swine anti mouse
antibody (1:200 dilution) and then for 30 min with avi-
din-biotin complexes (1:50 dilution) at 20°C. Diam-
inobenzidine (DAB) staining were Wnally followed by
haematoxylin nuclear counter staining. The slides were
dehydrated and mounted with a xylene-soluble mount-
ing medium.World J Urol (2007) 25:303–308 305
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Immunoreactivity scoring
The screening of tumour tissue samples was performed
by two independent investigators (CH and AH). The
sections were screened for positive cells, deWned as
cells with nuclear staining. The amount of Ki67 or p53
staining is scored in percentages. The threshold for p53
“positivity” is ¸20% positive staining. The areas with
maximal immunohistochemical staining were used for
scoring. In total, 300–500 tumour cells were scored. In
the visual estimation only deWnitely brown nuclei were
recorded as positive. The results were expressed as
percentage of immunoreactive tumour cell nuclei.
Results
Fifteen patients (11 males, 4 females) signed a patient
informed consent and participated in this study. Ages
ranged from 42 to 75 years (mean 63.2 years). All
patients underwent cystectomy for transitional cell car-
cinoma of the bladder. Eight patients had a de novo
invasive bladder tumour, whereas seven patients had a
history of high-risk superWcial disease. Patient details
are summarized in Table 1.
The initial biopsies and tumour tissues obtained
with cystectomy were used for histopathological diag-
nosis and immunohistochemical analysis of Ki-67 and
p53. The results from the diVerent treatment groups
are summarized in Table 2. In one patient of the MMC
group no residual tumour could be retrieved in the cys-
tectomy specimen. The proliferation activity and p53
activity could not be scored in that patient.
The intensity of inXammation increased in three out
of nine patients treated with hyperthermia. In three
out of Wve patients from the MMC group and control
group an increase was seen. The intensity of haemor-
rhage increased in four out of nine patients treated
with hyperthermia, one patient showed a decrease and
four patients did not show any diVerence. In the MMC
group and in the control group two patients showed an
increase, one patient a decrease and two patients did
not show any diVerence.
In six out of the nine patients treated with hyper-
thermia a decrease in proliferation activity in the
tumour tissue sample was found (Fig. 1a). In the MMC
group one patient showed a decrease and one showed
an increase in proliferation activity. In the control
group two out of three patients showed no changes,
whereas in one patient an increase in proliferation
activity was seen.
As regards p53, seven out of nine patients treated
with hyperthermia showed a decrease in p53 activity
(Fig. 1b). In one patient no change was found. The con-
trol group and the group treated with MMC did not
show any diVerences concerning p53.
Discussion
Thermo-chemotherapy has shown to be a promising
method for treating several kinds of malignant
tumours including superWcial bladder cancer [15].
While hyperthermia is important in cancer therapy, it
can also damage normal tissues adjacent to the
tumour. Fajardo [4] reviewed the eVects of hyperther-
mia from several studies on various tissues of mam-
mals and humans. Hyperthermia with a maximum
applied temperature of 44.5°C showed no gross or
microscopic alterations of the bladder of dogs and
Table 1 Patient details con-
taining number of previous 
occurrences, interval period 
between initial diagnosis and 
cystectomy in months, pathol-
ogy data of biopsy and cystec-
tomy (grading according to 
WHO 2002)
Groups Patient 
no/age/sex
N previous 
occurrences
Interval 
biopsy–cystectomy 
(in months)
Histopathology 
initial biopsy
Histopathology 
cystectomy
1 (MMC) 1/75/M 0 2,0 ¸pT2aGIII pT3aGIIIN2
2/46/F 0 4,4 pT2GII pT3bGIIIN1
3/67/F 0 1,2 ¸pT2GIII ¸pT2GIII 
2 (HT) 4/64/F 0 1,9 pT1GIII pT2aGIII
5/71/M 3 38,7 pT1GIII + CIS pT1GIII + CIS
6/42/M 10 121,9 pTaGII pTaGII
3 (MMC + HT) 7/55/M 0 2,6 pT1GIII ¸pT2GIII
8/67/M 0 1,9 pT2GIII pT3aGIIIN1
9/48/F 1 3,3 pT1GII pT2bGIIIN1
4 (History 
of MMC + HT)
10/54/M 18 107,5 pTaGII pTaGII
11/73/M 2 22,3 CIS pT4aGIIIN2
12/75/M 10 57,7 pTaGII pTaGII
5 (Control) 13/71/M 9 115,5 CIS pT2GIII
14/71/M 0 3,1 pT2GIII pT2GIII
15/71/M 0 3,3 pT2GIII pT2GIIIN1
HT microwave induced 
hyperthermia306 World J Urol (2007) 25:303–308
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Table 2 The p53 and Ki67 
immunoreactivity scorings in 
percentages of all patients di-
vided in Wve diVerent treat-
ment groups
Groups Material InXammation Proliferation (%) P53 (%) Haemorrhage
1 (MMC)
a Biopsy +++ 30 20 +
Cystectomy +++ 75 20 ++
bB i o p s y + + 2 0 7 5¡
Cystectomy +++ 15 75 +
c Biopsy +++ 40 75 +++
Cystectomy NA NA NA NA
2 (HT)
aB i o p s y + 6 0 8 0¡
Cystectomy +++ 20 40 ++
bB i o p s y + 3 0 9 0¡
Cystectomy ++ 20 40 ¡
c Biopsy + 10 - ¡
Cystectomy ++ 10 - +
3 (MMC + HT)
a Biopsy +++ 40 >75 ¡
Cystectomy +++ 25 75 ¡
b Biopsy +++ >75 >75 +
Cystectomy +++ 60 15 ¡
c Biopsy +++ 30 >75 +
Cystectomy +++ 15 75 ++
4 (History of MMC + HT)
aB i o p s y + 1 0 7 5¡
Cystectomy + 20 ¡¡
b Biopsy +++ 30 25 ¡
Cystectomy +++ 30 25 ¡
cB i o p s y + + 5 0 2 0¡
Cystectomy ++ 20 10 +
5 (Control)
a Biopsy + 15 >75 ¡
Cystectomy +++ 40 >75 ¡
bB i o p s y + + 4 0 2 0¡
Cystectomy ++ 40 20 ¡
cB i o p s y + + 3 5 7 5+
Cystectomy +++ 35 75 ¡
The extend of inXammation 
and haemorrhage is semi 
quantitatively scored (1+ to 
3+)
NA not applicable due to ab-
sence of residual tumour
Fig. 1 The p53 and Ki67 posi-
tive staining in patient no. 4 
(hyperthermia group).   
a1 shows 60% Ki67 positivity 
before treatment; a2 shows 
20% Ki67 positivity after 
treatment; b1 shows 80% p53 
positivity before treatment 
and b2 shows 40% p53 
positivity after treatmentWorld J Urol (2007) 25:303–308 307
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rabbits. Subsequently, Rath-Wolfson et al. [13] stud-
ied the eVect of hyperthermia, with a maximum
applied temperature of 46°C, and simultaneous MMC
treatment in sheep. In this study thermo-chemother-
apy showed no signiWcant macroscopic or microscopic
diVerences in the bladder wall as compared to a con-
trol group with untreated sheep.
In the current study the eVect of the combination
thermo-chemotherapy is compared with solely hyper-
thermia, solely chemotherapy and no treatment (con-
trol group) in human patients with high-grade
urothelial cell carcinoma of the bladder. The system
SB-TS 101 used to deliver local microwave induced
hyperthermia makes it possible to dose the hyperther-
mia very precisely [1]. In this study hyperthermia was
delivered within a temperature range of 41–42°C, the
clinical situation. This makes comparison between the
diVerent groups more accurate.
The sample size of the group studied is small due to
the fact that recruitment of patients was diYcult.
Patients had to agree on an extra treatment session
only two days before cystectomy, which did not give
them any beneWt at all.
The degree of inXammation increased in the group
treated with solely hyperthermia (N = 3), solely MMC
(N = 1) and the control group (N = 2). In the group
treated with thermo-chemotherapy 2 days before sur-
gery the degree of inXammation was initially already
maximal. In the group treated with a cycle of six
thermo-chemotherapy treatments during the last
3 months the degree of inXammation apparently had
returned to baseline again.
At least one patient per group (except the control
group) showed an increase in the degree of haemor-
rhage. Patients from group 1 (solely MMC) showed the
highest degree of haemorrhage.
Group 3 patients (treated with thermo-chemother-
apy prior to cystectomy) show in one patient an
increase, in one patient a decrease and in one patient a
stable extend of haemorrhage. This is in line with the
results from Rath-Wolfson et al. [13]. Nevertheless,
since solely MMC and solely hyperthermia gives an
increase in haemorrhage, it would have been logical to
Wnd a higher extend of haemorrhage after the combi-
nation of both treatments. Possibly, this is not found
due to the small sample size.
The inhibition of proliferation activity is one of the
most important goals in cancer treatment. All groups
treated with hyperthermia showed to a diVerent
extend a decrease in proliferation activity. Most
interesting are the three patients treated with
thermo-chemotherapy preceding transurethral resec-
tion. All three patients showed a decrease in prolifer-
ation activity. The control group on the other hand
shows in two patients no diVerence and in one patient
an increase in proliferation activity. In earlier in vitro
studies using hyperthermia and bladder cancer cell
lines, this decrease in cell proliferation due to hyper-
thermia combined with chemotherapeutic agents was
already shown [14,  16]. However, in these in vitro
studies solely hyperthermia did not cause a signiW-
cant decrease in cell proliferation. Nevertheless,
there is a diVerence between in vitro and in vivo stud-
ies. This in vivo study is the Wrst one showing a
decreased proliferation activity in humans treated
with microwave-induced hyperthermia with or with-
out MMC. The eVect of hyperthermia was seen in six
out of nine patients treated with hyperthermia pre-
ceding cystectomy.
Furthermore, the group treated with solely MMC
did not show a signiWcant decrease in proliferation
activity. This is probably due to the limited penetration
properties of this intravesical used drug, especially
after one single treatment.
p53 is known to be responsible for repair or apopto-
sis in response to DNA damage. The p53 activity, in
other words the expression of mutant p53, decreased
exclusively in patients treated with hyperthermia with
or without MMC.
Previous experiments showed that the p53 pathway
is heat sensitive and that the p53 protein is inactivated
at temperatures above 41°C [8,  9]. When cells were
heated to 42.5°C and returned to normal temperatures,
a strong p53 response with an increase in protein levels
was observed. In our study we found the opposite, but
the time interval between treatment and cystectomy
was with 2 days (group 3) and several months (group 4)
signiWcantly longer than the time interval used by
Guan et al. [8]. Furthermore the results of this study
are based on a small number of patients, which makes
statistic analysis unreliable. On the other hand, the cur-
rent results suggest that thermo-chemotherapy could
be an eVective treatment in patients with a p53 tumour
suppressor gene mutated tumour. In all, the results
show several trends and encourage carrying out larger
experimental studies.
Conclusion
The degree of inXammation and haemorrhage in blad-
der tumours did not increase in patients treated with
hyperthermia. This, in combination with a decrease in
proliferation activity and a decrease in p53 activity,
implies that thermo-chemotherapy is a safe and prom-
ising treatment.308 World J Urol (2007) 25:303–308
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